低钾血症 中国就医指南

Hypokalemia is a common electrolyte disorder characterized by a serum potassium concentration below 3.5 mmol/L. Potassium is a critical intracellular cation essential for maintaining resting membrane potential, neuromuscular excitability, cardiac conduction, and acid-base balance. Pathophysiologically, hypokalemia arises from one or more of three primary mechanisms: inadequate potassium intake (rare in developed settings), excessive potassium loss—most commonly via the kidneys (e.g., diuretic use, hyperaldosteronism, renal tubular acidosis) or gastrointestinal tract (e.g., vomiting, diarrhea, laxative abuse)—or transcellular shifts where potassium moves from extracellular to intracellular compartments (e.g., insulin administration, beta-2 agonist use, alkalosis). Chronic kidney disease, heart failure, and endocrine disorders—including primary aldosteronism, Cushing’s syndrome, and thyrotoxic periodic paralysis—significantly increase susceptibility. Epidemiologically, hypokalemia affects approximately 5–10% of hospitalized patients, with prevalence rising to 20% among those receiving loop or thiazide diuretics. Community-based studies suggest milder forms occur in 2–5% of adults, particularly older individuals and those with polypharmacy. Key risk factors include advanced age, chronic use of potassium-wasting diuretics, uncontrolled diabetes mellitus, alcohol use disorder, eating disorders, and prolonged fasting or malnutrition. Clinically, symptoms are often subtle at mild levels (3.0–3.5 mmol/L) but escalate with severity: fatigue, muscle weakness, cramps, constipation, and palpitations may precede life-threatening complications such as paralytic ileus, rhabdomyolysis, ventricular arrhythmias (e.g., ventricular tachycardia, torsades de pointes), and sudden cardiac death when potassium falls below 2.5 mmol/L. Importantly, even subclinical hypokalemia contributes to reduced exercise tolerance, sleep disturbances, cognitive fog, and diminished work capacity—cumulatively impairing health-related quality of life. Patients frequently report decreased daily functioning, anxiety around symptom recurrence, and medication burden, especially when long-term potassium supplementation or mineralocorticoid antagonist therapy is required. Early recognition and individualized management are vital not only to prevent acute decompensation but also to mitigate chronic cardiovascular remodeling, including left ventricular hypertrophy and increased arterial stiffness, which are increasingly linked to persistent potassium dysregulation in hypertension and heart failure populations.

# 低钾血症（内分泌科）治疗方案与费用明细

一、非手术/保守治疗方案

适用人群：血钾3.0–3.5 mmol/L无症状者，或轻中度症状（乏力、心悸）且病因明确（如利尿剂使用、腹泻）者。

• •口服补钾（氯化钾缓释片）：

- 高端档（进口缓释制剂）：480–900元/月

• •静脉补钾（住院监护下）：

• •必要检查费：血钾+钠+氯+肾功能+心电图+尿钾测定：320–480元

二、病因导向干预（内分泌科核心路径）

适用人群：继发于原发性醛固酮增多症、Liddle综合征、Bartter/Gitelman综合征等内分泌/遗传性病因者。

• •肾上腺CT+肾素-醛固酮立卧位试验+基因检测（选择性）：2,800–6,500元
• •醛固酮拮抗剂（螺内酯）长期管理：300–1,200元/月（依剂量及监测频率）

三、特殊复杂情况处理

适用人群：顽固性低钾（反复发作＞6个月）、合并严重心律失常、难治性高血压或肾上腺肿瘤需手术者。

• •多学科会诊（内分泌+泌尿外科+心内科）：800–1,500元/次
• •肾上腺腺瘤腹腔镜切除术（转泌尿外科）：38,000–52,000元（含术前激素评估、手术、病理、术后监护）

四、方案快速选择指南

• •预算＜1,000元/月：首选口服补钾+病因筛查（基础检查），适用于初发、可逆性病因；
• •预算2,000–8,000元：推荐住院静脉补钾+全套内分泌病因学评估；
• •疑难复发/疑似肿瘤：直接启动多学科评估，避免延误根治时机。